Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
77°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Altamira Therapeutics Ltd
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
August 23, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
August 16, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models
August 12, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
July 19, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
June 20, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Provides Business Update
May 28, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
May 23, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
May 01, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
April 24, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
April 10, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
April 04, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
March 25, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
February 07, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
January 24, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
January 08, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
December 29, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Provides Investor and Business Update
December 11, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics to Host Investor & Business Update Call on December 11th
December 05, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
November 29, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business
November 17, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine
November 10, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
September 14, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results
September 12, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th
September 06, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
August 23, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia
July 20, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal
July 17, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration
July 05, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics’ SemaPhore Delivery Platform Shows Significant Synergis-tic Effects of ZBTB46 mRNA with PD1 Immunotherapy in Control of Tumor Growth in Animal Model
March 22, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Files Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
February 27, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.